180 Life Sciences (ATNF) said Thursday that the US Patent and Trademark Office has issued a notice of allowance for a patent application covering a new method to prevent post-operative cognitive dysfunction, or POCD.
The patent centers on preventing or reducing POCD by using an anti-human tumor necrosis factor alpha monoclonal antibody before and during surgery.
POCD is a complication affecting elderly surgical patients that leads to delirium, memory loss, and other cognitive impairments, the company said.
180 Life Sciences said a patent, if issued, would boost its biotechnology portfolio while it shifts focus toward online casino and entertainment ventures through its gaming platform.
Shares of 180 Life Sciences were up 11% in recent Thursday trading.
Price: 0.99, Change: +0.10, Percent Change: +11.01
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。